z-logo
open-access-imgOpen Access
Apatinib for advanced nonsmall-cell lung cancer
Author(s) -
C. G. Yang,
Wen Feng,
Di Wu
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_258_17
Subject(s) - apatinib , medicine , common terminology criteria for adverse events , adverse effect , oncology , progressive disease , lung cancer , response evaluation criteria in solid tumors , cancer , tyrosine kinase inhibitor , gastroenterology , disease
Apatinib, a tyrosine kinase inhibitor which selectively inhibits vascular endothelial growth factor receptor-2, has been shown to be beneficial to patients with a variety of cancers, including advanced nonsmall-cell lung cancer (NSCLC). Thus, this study was aimed to retrospectively assess the efficacy and safety of apatinib in patients with advanced/metastatic NSCLC who failed more than two lines of treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here